Grifols Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Nacho Abia

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	9.5yrs
Promedio de permanencia en la Junta Directiva	8.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Nacho Abia (55 yo)

no data

Permanencia

Mr. Nacho Abia had been Chief Strategy Officer at Olympus Corporation since 2023 until April 01, 2024 and served as its Executive Officer since April 01, 2020 until April 01, 2024 and had been its Chief Op...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Glanzmann	Executive Chairman	18yrs	€150.00k	0.0058% € 292.6k
Nacho Abia	CEO & Director	no data	sin datos	sin datos
Alfredo Guerra	CFO & VP	17.3yrs	sin datos	sin datos
Eva Bastida Tubau	Corporate Vice President and Director of Scientific & Medical Affairs	17.3yrs	sin datos	sin datos
Nuria Lapeña	VP of Corporate Treasury	no data	sin datos	sin datos
David Bell	Chief Corporate Development	21.3yrs	sin datos	0.0029% € 149.1k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.3yrs	sin datos	0.00078% € 39.4k
Montserrat Llamas	Chief Human Resources Officer	no data	sin datos	0.00010% € 5.1k
Vicente Blanquer Torre	Chief Quality Officer	31.3yrs	sin datos	0.0066% € 333.0k
Alberto Roura	President of the Bio Supplies Division	6.3yrs	sin datos	0.0040% € 201.1k
Sergio Adell	President of Commercial Tech Support	5.3yrs	sin datos	sin datos
Joel Abelson	President of the Bioscience Commercial Division	12.8yrs	sin datos	sin datos

9.5yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: OZTAEl equipo directivo de la empresa es veterano y experimentado (5.9 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Glanzmann	Executive Chairman	18yrs	€150.00k	0.0058% € 292.6k
Nacho Abia	CEO & Director	less than a year	sin datos	sin datos
Albert Coma-Cros	Executive Director	less than a year	sin datos	0.0097% € 491.2k
Juan Twose Roura	Member of the Advisory Committee	9.3yrs	€380.00k	sin datos
Raimon Grifols Roura	Vice-Chairman	8.9yrs	€1.04m	0.00078% € 39.4k
Tomas Daga Gelabert	Independent External Director	24yrs	sin datos	0.022% € 1.1m
Inigo Mardones	Independent Director	8.9yrs	€150.00k	sin datos
Carina Szpilka Lázaro	Lead Independent Director	8.9yrs	€150.00k	0.00022% € 11.1k
Víctor Grifols Deu	Director	7.9yrs	€1.04m	0.0022% € 108.6k
James Costos	Independent Director	3.5yrs	€138.00k	sin datos
Enriqueta Font	Independent Director	4.9yrs	€125.00k	sin datos
Montserrat Abellana	Independent Director	1.8yrs	€63.00k	sin datos

8.4yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de OZTA se considera experimentada (8.3 años de antigüedad promedio).

Grifols Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Insufficient new directors

Recent updates

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 45%

Full year 2023 earnings released

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Third quarter 2023 earnings released

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Insufficient new directors

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Insufficient new directors

Grifols Announces Management Changes

Second quarter 2022 earnings released

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Now 21% undervalued

Full year 2021 earnings: Revenues miss analyst expectations

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Now 25% undervalued after recent price drop

Second quarter 2021 earnings released

Independent External Director Ramon Riera Roca has left the company

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

First quarter 2021 earnings released: EPS €0.19 (vs €0.27 in 1Q 2020)

Full year 2020 earnings released: EPS €0.90 (vs €0.91 in FY 2019)

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Full year 2020 earnings released: EPS €0.90 (vs €0.91 in FY 2019)

Revenue misses expectations

New 90-day low: €22.49

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Grifols Begins Clinical Trial of A New Treatment That Would Provide Immediate Immunity Against Covid-19

Grifols, S.A. Announces Board Appointments

Grifols, S.A. (BME:GRF) completed the acquisition of remaining 52.4% stake in Alkahest, Inc.

Grifols, S.A. Executes Binding Master Joint Venture Agreement with National Service Projects Organization

B. Braun Melsungen AG and Grifols Forms Strategic Alliance to Offer Integrated Solutions for Safe Automated Drug Preparation and Administration

Grifols, S.A. (BME:GRF) acquired remaining 49% stake in Goetech LLC for $60.2 million.

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.39

CEO

Permanencia

Equipo directivo